Application of fluorescence polarization immunoassay for determination of methotrexate-polyglutamates in rheumatoid arthritis patients

Tohoku Journal of Experimental Medicine

Volumn 215, Issue 1, 2008, Pages 95-101

  Hayashi, Hideki ^a   Fujimaki, Chihiro ^a   Tsuboi, Seiji ^b   Matsuyama, Taiji ^b   Daimon, Takashi ^a   Itoh, Kunihiko ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b Shizuoka Kousei Hospital   (Japan)

Author keywords

Fluorescence polarization immunoassay; Methotrexate; Methotrexate polyglutamate; Rheumatoid arthritis; Therapeutic drug monitoring

Indexed keywords

ANTIMETHOTREXATE MONOCLONAL ANTIBODY; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; MONOCLONAL ANTIBODY;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG ERYTHROCYTE LEVEL; DRUG MONITORING; DRUG PULSE THERAPY; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MAJOR CLINICAL STUDY; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS;

ADMINISTRATION, ORAL; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; INFLAMMATION MEDIATORS; METHOTREXATE; POLYGLUTAMIC ACID;

EID: 44849142991     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.215.95     Document Type: Article

References (22)

1. Allegra, C.J. & Boarman, D. (1990) Interaction of methotrexate polyglutamates and dihydrofolate during leucovorin rescue in a human breast cancer cell line (MCF-7). Cancer Res., 50, 3574-3578.
2. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum., 46, 328-346.
3. Andersen, P.A., West, S.G., O'Dell, J.R., Via, C.S., Claypool, R.G. & Kotzin, B.L. (1985) Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann. Intern. Med., 103, 489-496.
4. Angelis-Stoforidis, P., Vajda, F.J. & Christophidis, N. (1999) Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. Clin. Exp. Rheumatol., 17, 313-320.
5. Chan, E.S. & Cronstein, B.N. (2002) Molecular action of methotrexate in inflammatory diseases. Arthritis Res., 4, 266-273.
6. Dervieux, T., Kremer, J., Lein, D.O., Capps, R., Barham, R., Meyer, G., Smith, K., Caldwell, J. & Furst, D.E. (2004) Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics, 14, 733-739.
7. Dervieux, T., Orentas Lein, D., Marcelletti, J., Pischel, K., Smith, K., Walsh, M. & Richerson, R. (2003) HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin. Chem., 49, 1632-1641.
8. Evans, W.E., Relling, M.V., Rodman, J.H., Crom, W.R., Boyett, J.M. & Pui, C.H. (1998) Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N. Engl. J. Med., 338, 499-505.
9. Goldman, I.D., Lichtenstein, N.S. & Oliverio, V.T. (1968) Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J. Biol. Chem., 243, 5007-5017.
10. Gorlick, R., Goker, E., Trippett, T., Waltham, M., Banerjee, D. & Bertino, J.R. (1996) Intrinsic and acquired resistance to methotrexate in acute leukemia. N. Engl. J. Med., 335, 1041-1048.
11. Kamen, B.A., Takach, P.L., Vatev, R. & Caston, J.D. (1976) A rapid, radiochemical-ligand binding assay for methotrexate. Anal. Biochem., 70, 54-63.
12. Kamen, B.A. & Winick, N. (1986) Analysis of methotrexate polyglutamate derivatives in vivo. Methods Enzynol., 122, 339-346.
13. Matherly, L. H., Fry, D.W. & Goldman, I.D. (1983) Role of methotrexate polyglutamylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5-formyltetrahydrofolate in Ehrlich ascites tumor cells in vitro. Cancer Res., 43, 2694-2699.
14. Pui, C.H., Campana, D. & Evans, W.E. (2001) Childhood acute lymphoblastic leukaemia-current status and future perspectives. Lancet Oncol., 2, 597-607.
15. Pui, C.H. & Evans, W.E. (1998) Acute lymphoblastic leukemia. N. Engl. J. Med., 339, 605-615.
16. Ranganathan, P., Eisen, S., Yokoyama, W.M. & McLeod, H.L. (2003) Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis? Ann. Rheum. Dis., 62, 4-9.
17. Schroder, H. & Heinsvig, E.M. (1985) Enzymatic assay for methotrexate in erythrocytes. Scand. J. Clin. Lab. Invest., 45, 657-659.
18. Shane, B. (1989) Folylpolyglutamate synthesis and role in the regulation of one-carbon metabolism. Vitam. Horm., 45, 263-335.
19. Stoller, R.G., Hande, K.R., Jacobs, S.A., Rosenberg, S.A., & Chabner, B.A. (1977) Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N. Engl. J. Med., 297, 630-634.
20. Treon, S.P. & Chabner, B.A. (1996) Concepts in use of high-dose methotrexate therapy. Clin. Chem., 42, 1322-1329.
21. Weinblatt, M.E., Coblyn, J.S., Fox, D.A., Fraser, P.A., Holdsworth, D.E., Glass, D.N. & Trentham, D.E. (1985) Efficacy of low-dose methotrexate in rheumatoid arthritis. N. Engl. J. Med., 312, 818-822.
22. Zhao, R. & Goldman, I.D. (2003) Resistance to antifolates. Oncogene, 22, 7431-7457.